MX2015011456A - Derivados de 3-(arilo o heteroailo) metilenindolino-2-ona como inhibidores de cinasas de la via de las celulas madres cancerosas para el tratamiento del cancer. - Google Patents
Derivados de 3-(arilo o heteroailo) metilenindolino-2-ona como inhibidores de cinasas de la via de las celulas madres cancerosas para el tratamiento del cancer.Info
- Publication number
- MX2015011456A MX2015011456A MX2015011456A MX2015011456A MX2015011456A MX 2015011456 A MX2015011456 A MX 2015011456A MX 2015011456 A MX2015011456 A MX 2015011456A MX 2015011456 A MX2015011456 A MX 2015011456A MX 2015011456 A MX2015011456 A MX 2015011456A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- inhibitors
- treatment
- stem cell
- aryl
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 201000011510 cancer Diseases 0.000 title abstract 5
- 210000000130 stem cell Anatomy 0.000 title abstract 3
- 108091000080 Phosphotransferase Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000037361 pathway Effects 0.000 title abstract 2
- 102000020233 phosphotransferase Human genes 0.000 title abstract 2
- IGXUUWYVUGBMFT-UHFFFAOYSA-N 3-methyleneoxindole Chemical class C1=CC=C2C(=C)C(=O)NC2=C1 IGXUUWYVUGBMFT-UHFFFAOYSA-N 0.000 title 1
- 125000001072 heteroaryl group Chemical group 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000003107 substituted aryl group Chemical group 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361780248P | 2013-03-13 | 2013-03-13 | |
| US201361780263P | 2013-03-13 | 2013-03-13 | |
| PCT/US2014/026498 WO2014160401A1 (en) | 2013-03-13 | 2014-03-13 | 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015011456A true MX2015011456A (es) | 2016-05-31 |
Family
ID=50639949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015011456A MX2015011456A (es) | 2013-03-13 | 2014-03-13 | Derivados de 3-(arilo o heteroailo) metilenindolino-2-ona como inhibidores de cinasas de la via de las celulas madres cancerosas para el tratamiento del cancer. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20160031888A1 (enExample) |
| EP (1) | EP2970206A1 (enExample) |
| JP (2) | JP6378308B2 (enExample) |
| KR (1) | KR20150127249A (enExample) |
| CN (1) | CN105408320B (enExample) |
| AU (2) | AU2014243869A1 (enExample) |
| BR (1) | BR112015022431A2 (enExample) |
| CA (1) | CA2904152A1 (enExample) |
| HK (1) | HK1220184A1 (enExample) |
| IL (1) | IL240960A0 (enExample) |
| MX (1) | MX2015011456A (enExample) |
| RU (2) | RU2019104092A (enExample) |
| SG (2) | SG11201507346PA (enExample) |
| WO (1) | WO2014160401A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104876928B (zh) * | 2015-05-07 | 2016-09-14 | 浙江司太立制药股份有限公司 | 7-氮杂吲哚啉-2-酮类化合物及其制备方法 |
| JPWO2017026119A1 (ja) * | 2015-08-10 | 2018-05-24 | 大日本住友製薬株式会社 | ５−（チアゾール−４−イル）インドリン−２−オン誘導体の精製方法 |
| EA201891136A1 (ru) * | 2015-11-12 | 2018-10-31 | ЭлДжи КЕМ, ЛТД. | Фармацевтическая композиция, содержащая в качестве активного ингредиента производное 7-азаиндолин-2-она или его фармацевтически приемлемую соль |
| CN105461705B (zh) * | 2015-11-30 | 2018-04-10 | 中国医科大学 | 二苯并氮杂卓二酮类抗肿瘤化合物及其制备方法 |
| WO2018005444A2 (en) | 2016-06-28 | 2018-01-04 | Boston Biomedical, Inc. | Methods for treating cancer |
| CN107698593A (zh) * | 2016-08-09 | 2018-02-16 | 南京天印健华医药科技有限公司 | 作为fgfr抑制剂的杂环化合物 |
| CN106432228A (zh) * | 2016-09-06 | 2017-02-22 | 浙江司太立制药股份有限公司 | 含有4‑肟基‑1‑哌啶基片段的7‑氮杂吲哚啉‑2‑酮类化合物及其制备方法 |
| CN106397436A (zh) * | 2016-09-06 | 2017-02-15 | 浙江司太立制药股份有限公司 | 5‑溴‑7‑氮杂吲哚啉‑2‑酮类化合物及其制备方法 |
| WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
| WO2019002889A1 (en) | 2017-06-30 | 2019-01-03 | Industrial Technology Research Institute | METHOD FOR TREATING AUTOIMMUNE NEUROLOGICAL DISEASE AND / OR NEURODEGENERATIVE DISEASE AND PHARMACEUTICAL FORMULAS FOR LIQUID GALENIC FORM AND CONTROLLED RELEASE GALENIC FORM |
| CN110357878B (zh) * | 2018-03-26 | 2022-04-12 | 武汉誉祥医药科技有限公司 | 1,3-二氢-2H-吡咯并[3,2-b]吡啶-2-酮衍生物及其医药用途 |
| UA127357C2 (uk) | 2018-04-18 | 2023-07-26 | Констеллатіон Фармацеутікалс, Інк. | Модулятори метилмодифікуючих ферментів, композиції та їх використання |
| EP3797108B1 (en) | 2018-05-21 | 2022-07-20 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US12318381B2 (en) * | 2018-09-18 | 2025-06-03 | 1Globe Biomedical Co., Ltd. | Treatment for non-alcoholic fatty liver disease |
| JP7589949B2 (ja) * | 2018-09-18 | 2024-11-26 | １グローブ バイオメディカル カンパニー， リミテッド | 肥満に対する処置 |
| WO2021003339A1 (en) * | 2019-07-03 | 2021-01-07 | The Regents Of The University Of Colorado, A Body Corporate | Amp-activated protein kinase inhibitors and methods of making and using the same |
| MD4003532T2 (ro) | 2019-07-24 | 2025-01-31 | Constellation Pharmaceuticals Inc | Forme cristaline de 7-clor-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-N-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamidă |
| US20230212120A1 (en) * | 2020-05-29 | 2023-07-06 | The Regents Of The University Of Michigan | Small molecule inhibitors of grk5 and grk5 subfamily members and uses thereof |
| CN111675647B (zh) * | 2020-06-26 | 2022-03-01 | 深圳技术大学 | 2-吲哚酮类pak1抑制剂及其在抗肿瘤治疗药物中的应用 |
| KR20230037564A (ko) * | 2020-07-10 | 2023-03-16 | 블로썸힐 테라퓨틱스, 인크. | 거대고리 화합물 및 그의 용도 |
| CA3246487A1 (en) * | 2022-01-05 | 2023-07-13 | Blossomhill Therapeutics, Inc. | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS |
| CN114213396B (zh) * | 2022-01-27 | 2023-03-24 | 深圳市乐土生物医药有限公司 | 一种吲哚-2-酮类化合物及其制备方法与用途 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE640616A (enExample) | 1962-12-19 | |||
| US3492397A (en) | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
| US4060598A (en) | 1967-06-28 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Tablets coated with aqueous resin dispersions |
| US3538214A (en) | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
| US4173626A (en) | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
| WO1997013767A1 (de) * | 1995-10-09 | 1997-04-17 | Chemisch Pharmazeutische Forschungsgesellschaft Mbh | Heterocyclisch substituierte 1-indolcarboxamide als cyclooxygenase-2 inhibitoren |
| GB9716557D0 (en) * | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| BR9916223A (pt) * | 1998-12-17 | 2001-09-04 | Hoffmann La Roche | 4-ariloxindóis como inibidores de cinases de proteìna jnk |
| AU2728201A (en) * | 1999-12-21 | 2001-07-03 | Sugen, Inc. | 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors |
| DE122008000002I1 (de) * | 2000-02-15 | 2008-04-17 | Sugen Inc | Pyrrol substituierte indolin-2-on protein kinase inhibitoren |
| US6635640B2 (en) * | 2000-06-30 | 2003-10-21 | Sugen, Inc. | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors |
| WO2002055517A2 (en) * | 2000-12-20 | 2002-07-18 | Jingrong Cui | 4-(hetero)aryl substituted indolinones |
| AR038957A1 (es) * | 2001-08-15 | 2005-02-02 | Pharmacia Corp | Terapia de combinacion para el tratamiento del cancer |
| AU2004284084A1 (en) * | 2003-10-24 | 2005-05-06 | Schering Aktiengesellschaft | Indolinone derivatives and their use in treating disease-states such as cancer |
| EP1828123A1 (en) * | 2004-12-17 | 2007-09-05 | Boehringer Ingelheim International GmbH | Indolinones and their use as antiproliferative agents |
| US20070032555A1 (en) | 2005-07-01 | 2007-02-08 | Concert Pharmaceuticals Inc. | Novel aryloxyphenyl-propanamines |
| US20070116643A1 (en) | 2005-07-01 | 2007-05-24 | Concert Pharmaceuticals Inc. | Novel aryloxypropanamines |
| WO2007016431A2 (en) | 2005-07-29 | 2007-02-08 | Concert Pharmaceuticals Inc. | Novel benzo [d] [1,3]-dioxol derivatives |
| WO2007016361A2 (en) | 2005-07-29 | 2007-02-08 | Concert Pharmaceuticals Inc. | Novel pharmaceutical compounds |
| EP1981884B1 (en) * | 2006-01-18 | 2012-06-13 | Amgen, Inc | Thiazole compounds as protein kinase b (pkb) inhibitors |
| CN101007801A (zh) * | 2006-01-27 | 2007-08-01 | 上海恒瑞医药有限公司 | 吡咯取代的2－二氢吲哚酮衍生物、其制法与医药上的用途 |
| WO2008045627A2 (en) * | 2006-10-06 | 2008-04-17 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
| CN101848908B (zh) * | 2007-09-06 | 2014-07-02 | 北京强新生物科技有限公司 | 激酶抑制剂的组合物及其在治疗癌症和其它与激酶相关的疾病中的用途 |
| EA019507B1 (ru) * | 2008-05-13 | 2014-04-30 | Айрм Ллк | Конденсированные азотсодержащие гетероциклы и содержащие их композиции в качестве ингибиторов киназы |
| US8853420B2 (en) * | 2008-07-29 | 2014-10-07 | Boehringer Ingelheim International Gmbh | Compounds |
| US9187454B2 (en) * | 2013-03-13 | 2015-11-17 | Boston Biomedical, Inc. | Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof |
| US9227962B2 (en) * | 2013-03-13 | 2016-01-05 | Boston Biomedical, Inc. | Heterocyclic substituted-3-heteroarylidenyl-2-indolinone derivative |
| US9795595B2 (en) * | 2014-01-27 | 2017-10-24 | Boston Biomedical, Inc. | Methods for treating cancer |
-
2014
- 2014-03-13 EP EP14721620.4A patent/EP2970206A1/en not_active Withdrawn
- 2014-03-13 SG SG11201507346PA patent/SG11201507346PA/en unknown
- 2014-03-13 MX MX2015011456A patent/MX2015011456A/es unknown
- 2014-03-13 SG SG10201806965XA patent/SG10201806965XA/en unknown
- 2014-03-13 KR KR1020157028817A patent/KR20150127249A/ko not_active Ceased
- 2014-03-13 CA CA2904152A patent/CA2904152A1/en not_active Abandoned
- 2014-03-13 AU AU2014243869A patent/AU2014243869A1/en not_active Abandoned
- 2014-03-13 CN CN201480026333.XA patent/CN105408320B/zh active Active
- 2014-03-13 RU RU2019104092A patent/RU2019104092A/ru unknown
- 2014-03-13 BR BR112015022431A patent/BR112015022431A2/pt not_active Application Discontinuation
- 2014-03-13 RU RU2015143526A patent/RU2015143526A/ru not_active Application Discontinuation
- 2014-03-13 US US14/774,803 patent/US20160031888A1/en not_active Abandoned
- 2014-03-13 JP JP2016502156A patent/JP6378308B2/ja not_active Expired - Fee Related
- 2014-03-13 HK HK16108180.5A patent/HK1220184A1/zh unknown
- 2014-03-13 WO PCT/US2014/026498 patent/WO2014160401A1/en not_active Ceased
-
2015
- 2015-08-31 IL IL240960A patent/IL240960A0/en unknown
-
2018
- 2018-07-06 JP JP2018129002A patent/JP2018168187A/ja active Pending
- 2018-09-21 AU AU2018233033A patent/AU2018233033A1/en not_active Abandoned
- 2018-11-30 US US16/206,010 patent/US20190241569A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HK1220184A1 (zh) | 2017-04-28 |
| JP6378308B2 (ja) | 2018-08-22 |
| CN105408320B (zh) | 2019-08-13 |
| IL240960A0 (en) | 2015-11-30 |
| AU2014243869A1 (en) | 2015-09-24 |
| CN105408320A (zh) | 2016-03-16 |
| US20160031888A1 (en) | 2016-02-04 |
| AU2018233033A1 (en) | 2018-10-11 |
| SG11201507346PA (en) | 2015-10-29 |
| CA2904152A1 (en) | 2014-10-02 |
| US20190241569A1 (en) | 2019-08-08 |
| JP2018168187A (ja) | 2018-11-01 |
| JP2016513656A (ja) | 2016-05-16 |
| KR20150127249A (ko) | 2015-11-16 |
| WO2014160401A1 (en) | 2014-10-02 |
| SG10201806965XA (en) | 2018-09-27 |
| BR112015022431A2 (pt) | 2017-05-09 |
| RU2015143526A (ru) | 2017-04-19 |
| RU2019104092A (ru) | 2019-03-20 |
| EP2970206A1 (en) | 2016-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015011456A (es) | Derivados de 3-(arilo o heteroailo) metilenindolino-2-ona como inhibidores de cinasas de la via de las celulas madres cancerosas para el tratamiento del cancer. | |
| MY173126A (en) | Arylquinazolines | |
| CY1120635T1 (el) | Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης | |
| EA201591913A1 (ru) | Ингибиторы протеинкиназы | |
| PH12017502090A1 (en) | Heterocyclic amides as kinase inhibitors | |
| PH12015501996A1 (en) | Heterocyclic compounds and uses thereof | |
| NZ711376A (en) | Heteroaryl compounds and uses thereof | |
| PH12016501972B1 (en) | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors | |
| EA201590920A1 (ru) | Гетероарилзамещённые пиридильные соединения, применимые в качестве модуляторов киназ | |
| EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
| EA201300080A1 (ru) | Дипиридильные производные, пригодные для лечения заболеваний, индуцированных киназами | |
| MX368066B (es) | Derivados de quinazolin-4-ona sustituida. | |
| MX2012013197A (es) | Inhibidores de indazol de cinasa. | |
| MX344335B (es) | Derivados de benzonitrilo como inhibidores de cinasa. | |
| MX2013001361A (es) | 4-(1h-indol-3-il) - pirimidina como inhibidores de alk. | |
| PH12015502611A1 (en) | Heterocyclic compounds as hedgehog signaling pathway inhibitors | |
| MX341456B (es) | Amino-quinolinas como inhibidores de cinasa. | |
| MX2018008362A (es) | Derivados de quinolin-2-ona. | |
| EA201590552A1 (ru) | Аминохинолины в качестве ингибиторов киназы | |
| PH12016500347A1 (en) | Triazolopyridine compounds, compositions and methods of use thereof | |
| GEP20166489B (en) | 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors | |
| MX2015012386A (es) | Inhibidores de la cinasa cdk9. | |
| MX2016007810A (es) | Derivados de n1-(3,3,3-trifluoro-2-hidroxo-2-metilpropionil)-piper idina como inhibidores de piruvato deshidrogenasa cinasa. | |
| MX370448B (es) | Derivados de 6- [4- (1h-imidazol-2-il) piperidin-1-il] pirimidin-4-amina como moduladores de la actividad de cinasa. | |
| MX2015012153A (es) | Inhibidores de la quinasa pirrolopirimidina cdk9. |